The Russian Ministry of Health has announced the development of a groundbreaking mRNA-based cancer vaccine, which will be provided to patients free of charge starting in early 2025.
The news, revealed by Andrey Kaprin, General Director of the Radiology Medical Research Center, highlights a significant stride in oncology treatment aimed at reducing financial burdens for patients.
The vaccine, developed in collaboration with the Gamaleya National Research Center for Epidemiology and Microbiology, targets cancer treatment rather than prevention.
READ: Joe Rogan Rips Bill Gates Over COVID Profits, Claims Vaccine Push Ruined Millions Of Lives
Unlike traditional cancer therapies, this vaccine will be personalized for each patient, leveraging advanced technologies such as artificial intelligence to optimize treatment outcomes.
According to Alexander Gintsburg, Director of the Gamaleya Center, preclinical trials have shown promising results. The vaccine successfully suppressed tumor growth by 75-80% and reduced the risk of metastases, particularly in adenocarcinomas — cancers that originate in glandular cells of organs like the colon, breast, lung, and pancreas.
Kaprin emphasized that the vaccine’s free distribution will democratize access to critical treatments, ensuring it is not limited to only those with significant financial resources.
“Cancer drugs are often prohibitively expensive when they are first introduced. This initiative aims to provide life-saving care to all who need it,” Kaprin stated.
READ: Covert U.S. Campaign Targeted China’s Vaccine Efforts During Pandemic, Sources Say
The Russian Health Ministry announced that clinical trials for the vaccine began in June, involving patients aged 18 to 75 who were not undergoing active chemotherapy.
The trials were expected to evaluate the vaccine’s safety and efficacy further.
Health Minister Mikhail Murashko previously noted that the research and development of the vaccine were funded by the state. Teams of scientists from prominent institutes, including the Hertsen Moscow Oncology Research Institute and the Blokhin Cancer Research Center, contributed to the project.
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Connect with us: Follow the Tampa Free Press on Facebook and Twitter for breaking news and updates.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox.